CLINICAL TRIALS PROFILE FOR TUKYSA
✉ Email this page to a colleague
All Clinical Trials for Tukysa
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT03043313 ↗ | Tucatinib Plus Trastuzumab in Patients With HER2+ Colorectal Cancer | Active, not recruiting | Academic and Community Cancer Research United | Phase 2 | 2017-06-23 | This trial studies how well the drug tucatinib works when given with trastuzumab and when given by itself. The participants in this trial have HER2-positive (HER2+) metastatic colorectal cancer (mCRC). 'Metastatic' means that the cancer has spread to other parts of the body. In the first part of this study, participants enrolled into Cohort A and received both tucatinib and trastuzumab. In the second part of this study, participants are randomly assigned to either Cohort B or Cohort C. Participants in Cohort B will receive tucatinib and trastuzumab. Participants in Cohort C will receive tucatinib. Participants in Cohort C who do not respond to therapy may have an option to receive tucatinib plus trastuzumab. |
| NCT03043313 ↗ | Tucatinib Plus Trastuzumab in Patients With HER2+ Colorectal Cancer | Active, not recruiting | Cascadian Therapeutics Inc. | Phase 2 | 2017-06-23 | This trial studies how well the drug tucatinib works when given with trastuzumab and when given by itself. The participants in this trial have HER2-positive (HER2+) metastatic colorectal cancer (mCRC). 'Metastatic' means that the cancer has spread to other parts of the body. In the first part of this study, participants enrolled into Cohort A and received both tucatinib and trastuzumab. In the second part of this study, participants are randomly assigned to either Cohort B or Cohort C. Participants in Cohort B will receive tucatinib and trastuzumab. Participants in Cohort C will receive tucatinib. Participants in Cohort C who do not respond to therapy may have an option to receive tucatinib plus trastuzumab. |
| NCT03043313 ↗ | Tucatinib Plus Trastuzumab in Patients With HER2+ Colorectal Cancer | Active, not recruiting | National Cancer Institute (NCI) | Phase 2 | 2017-06-23 | This trial studies how well the drug tucatinib works when given with trastuzumab and when given by itself. The participants in this trial have HER2-positive (HER2+) metastatic colorectal cancer (mCRC). 'Metastatic' means that the cancer has spread to other parts of the body. In the first part of this study, participants enrolled into Cohort A and received both tucatinib and trastuzumab. In the second part of this study, participants are randomly assigned to either Cohort B or Cohort C. Participants in Cohort B will receive tucatinib and trastuzumab. Participants in Cohort C will receive tucatinib. Participants in Cohort C who do not respond to therapy may have an option to receive tucatinib plus trastuzumab. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Tukysa
Condition Name
Clinical Trial Locations for Tukysa
Trials by Country
Clinical Trial Progress for Tukysa
Clinical Trial Phase
Clinical Trial Sponsors for Tukysa
Sponsor Name
